SUV39H2 and prostate carcinoma: Specifically, the knockdown of SUV39H2 in prostate cancer cells led to a marked reduction in the expression of key stemness markers, including SOX2, NANOG, CD44, CD133, and octamer-binding transcription factor 4 (OCT4) (Sun et al., 2024).